Trial Information

Despite the therapeutic improvements with recent biologic agents approved for rheumatoid
arthritis (RA), there is still a significant unmet medical need for the treatment of
subjects with this chronic disease to achieve a faster, more complete response, and higher
rates of remission. The aim of the current study is to compare the efficacy and safety of a
subcutaneous dose of mavrilimumab with a marketed treatment for RA (golimumab) in 120 adult
subjects with moderate-to-severe active RA who have had an inadequate response to one or two
anti-TNF agents with mavrilimumab

Inclusion Criteria:

- A diagnosis of at least moderately-active adult onset RA

- At least 4 swollen joints

- Inadequate response to one or two anti-TNF agents other than the study comparator, as
defined by the protocol

- Receiving oral or injectable methotrexate, as defined by the protocol.

Exclusion Criteria:

- A rheumatic autoimmune disease or other inflammatory joint disease other than RA

- Previous treatment with biologic therapies other than anti-TNF for RA.

Study ID:

NCT ID:

Start Date:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.